204 related articles for article (PubMed ID: 17269614)
1. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification.
Ankerst DP; Thompson IM
Arch Ital Urol Androl; 2006 Dec; 78(4):125-9. PubMed ID: 17269614
[TBL] [Abstract][Full Text] [Related]
2. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
[TBL] [Abstract][Full Text] [Related]
3. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
[TBL] [Abstract][Full Text] [Related]
5. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.
Andriole GL; Guess HA; Epstein JI; Wise H; Kadmon D; Crawford ED; Hudson P; Jackson CL; Romas NA; Patterson L; Cook TJ; Waldstreicher J
Urology; 1998 Aug; 52(2):195-201; discussion 201-2. PubMed ID: 9697781
[TBL] [Abstract][Full Text] [Related]
6. Prostate Cancer Prevention Trial (PCPT) update.
Coltman CA; Thompson IM; Feigl P
Eur Urol; 1999; 35(5-6):544-7. PubMed ID: 10325520
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
Thompson IM; Pauler DK; Goodman PJ; Tangen CM; Lucia MS; Parnes HL; Minasian LM; Ford LG; Lippman SM; Crawford ED; Crowley JJ; Coltman CA
N Engl J Med; 2004 May; 350(22):2239-46. PubMed ID: 15163773
[TBL] [Abstract][Full Text] [Related]
8. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
9. Effect of finasteride on the sensitivity of PSA to detect prostate cancer in rebiopsy series.
Oderda M; Zitella A; Richiardi L; Tizzani A; Gontero P
Arch Ital Urol Androl; 2010 Dec; 82(4):135-8. PubMed ID: 21341547
[TBL] [Abstract][Full Text] [Related]
10. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
[TBL] [Abstract][Full Text] [Related]
11. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.
Roehrborn CG; Boyle P; Bergner D; Gray T; Gittelman M; Shown T; Melman A; Bracken RB; deVere White R; Taylor A; Wang D; Waldstreicher J
Urology; 1999 Oct; 54(4):662-9. PubMed ID: 10510925
[TBL] [Abstract][Full Text] [Related]
12. [Practical follow-up of a patient treated with finasteride in screening for prostate cancer].
Villers A
Prog Urol; 2008 Apr; 18 Suppl 3():S58-62. PubMed ID: 18455086
[TBL] [Abstract][Full Text] [Related]
13. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Parnes HL; Lippman SM; Coltman CA
J Urol; 2007 May; 177(5):1749-52. PubMed ID: 17437804
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
15. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.
Lucia MS; Darke AK; Goodman PJ; La Rosa FG; Parnes HL; Ford LG; Coltman CA; Thompson IM
Cancer Prev Res (Phila); 2008 Aug; 1(3):167-73. PubMed ID: 19138952
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer prevention and finasteride.
D'Amico AV; Barry MJ
J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
[TBL] [Abstract][Full Text] [Related]
17. The effect of finasteride on prostate specific antigen: review of available data.
Guess HA; Gormley GJ; Stoner E; Oesterling JE
J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
[TBL] [Abstract][Full Text] [Related]
18. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Finasteride PSA Study Group.
Oesterling JE; Roy J; Agha A; Shown T; Krarup T; Johansen T; Lagerkvist M; Gormley G; Bach M; Waldstreicher J
Urology; 1998 Apr; 51(4A Suppl):58-63. PubMed ID: 9586598
[TBL] [Abstract][Full Text] [Related]
19. Merging digital rectal exam, family history, age and prostate-specific antigen to create a decision-making tool.
Ankerst DP; Thompson IM
Arch Ital Urol Androl; 2006 Dec; 78(4):143-6. PubMed ID: 17269618
[TBL] [Abstract][Full Text] [Related]
20. [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].
Schmitz-Dräger BJ; Fischer C; Bismarck E; Dörsam HJ; Lümmen G
Urologe A; 2007 Oct; 46(10):1364, 1366-8, 1370. PubMed ID: 17874228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
